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Abstract
Background: Growth factor-binding proteins influence
the growth of infants starting in utero. Adaptation of the
fetus to an adverse uterine environment is associated
with changes in the growth hormone-growth factor-
insulin axis.
Aims: To evaluate serum levels of IGF-I and IGFBP-3
in small and appropriate for gestational age newborn
infants.
Methods: Fifty-four newborn infants, small (SGA, ns28)
or appropriate (AGA, ns26) for gestational age were
matched by gestational age and sex. Blood was collect-
ed on the first day of life, and anthropometric measure-
ments were taken at birth. The serum levels of IGF-I and
IGFBP-3 were compared, and correlated with the anthro-
pometric measurements.
Results: On the first day of life, mean serum IGFBP-3
levels were significantly lower in SGA babies and corre-
lated with weight, length, head circumference, and pon-
deral index (weight/length 3) (P-0.0001). In contrast, no
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associations were found between IGF-I serum levels and
these anthropometric measurements.
Conclusion: Our data show that SGA babies have sig-
nificantly reduced IGFBP-3 concentrations at birth.
Keywords: IGF-binding protein-3; insulin-like growth
factor-I; small for gestational age.
Introduction
Insulin growth factors have a central role in fetal-
placental growth throughout gestation. It has been
shown that insulin-like growth factor (IGF)-I levels at birth
are lower in small for gestational age (SGA) than in appro-
priate for gestational age (AGA) preterm newborns w10,
20x, although other studies evaluating only term SGA
newborns found higher IGF-I levels w29, 32x than in AGA
infants. Changes in the hormonal milieu may be a con-
sequence of the adaptation of the fetus during intrauter-
ine life to a hostile environment of maternal, placental or
fetal origin in order to improve survival. Many studies
have shown that this adaptation has consequences
either in the neonatal period or later w8, 14, 26x; for exam-
ple, there is the high risk of developing insulin resistance
at the end of childhood or as young adults for SGA and
premature children w6, 11, 12, 21, 33x. The endocrine re-
programming that occurs in this population is the result
of modifications in the growth hormone-growth factor-
insulin axis during intra-uterine life and is influenced by
nutrition in the first post-natal weeks w1, 28x.
In addition, circulating IGF-1 forms complexes with
binding proteins (IGFBPs), whose physiological functions
include transport, reservoir, protection from proteolytic
degradation, and the ability to activate receptors on
target cells w27x. Therefore, serum IGFBPs, especially
IGFBP-3 w15, 30x, are important markers of growth.
In this study, we evaluated the serum levels of IGF-I
and IGFBP-3 in SGA and AGA newborn infants at birth,
matched by gestational age and sex, to test the hypoth-
esis that intrauterine growth restriction is associated with
these hormones early in life.
Methods
All SGA newborn infants born between 1 July 2005 and
31 June 2006 at the Instituto Fernandes Figueira maternity, Rio
de Janeiro, Brazil, were included in the study. SGA newborn
infants were matched with AGA newborn infants, born in the
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Table 1 Characteristics at birth of the small for gestational age (SGA) and appropriate for gestational age (AGA) newborn infants.
Variable SGA (28) AGA (26) P-value
Mean (SD) Mean (SD)
Maternal age, years 25.7 (6.8) 27.1 (9.8) 0.54
Gestational age, weeks 35.0 (3.5) 35.0 (3.6) 0.96
Weight, g 1500 (599) 2437 (716) -0.0001
Length, cm 41.0 (5.5) 47.4 (4.7) -0.0001
Head circumference, cm 29.0 (3.3) 32.2 (2.5) -0.0001
n (%) n (%)
Sex, male 8/28 7/26 0.86
Premature* 17/28 15/26 0.96
Multiple gestation 5/28 6/26 0.89
Cesarean section 25/28 17/24 0.15
APGAR (5 min) F6 4/28 1/26 0.19
Smokers 5/28 4/25 0.57
Alcohol use 1/22 7/23 0.04
Maternal hypertension 16/27 9/25 0.16
Oligodramnious 12/26 6/24 0.20
Premature rupture of membranes 2/23 5/25 0.41
*14/54 (25.6%) gestational age -33 weeks.
SDsstandard deviation, SGAssmall for gestational age, AGAsappropriate for gestational age.
same period and unit, by gestational age and sex. The exclusion
criteria were congenital malformations, congenital infections and
genetic syndromes.
SGA was defined as birth weight F2 SD (standard deviation)
below the mean (weight for age Z-score, Fy2 SD) using the
Kramer’s reference data w16x, a restricted definition by the inter-
national consensus published by Lee et al. w19x. The children
with birth weights above the cut-off were considered AGA. Ges-
tational age was calculated from the last menstrual period (40),
early ultrasound (9), or the New Ballard score (5), in that order
of preference.
Anthropometric measurements were taken at birth by trained
nurses. Weight was measured with a digital scale (precision of
5 g). An appropriate scale for an incubator was used for length
measurements and an inextensible tape was used for head cir-
cumference measurements. Blood samples were taken on the
first day of life.
Serum IGF-I and IGFBP-3 levels were measured in the
Laboratório de Fisiologia da Nutricão e do Desenvolvimento,¸
Departamento de Ciências Fisiológicas, IBRAG, Universidade do
Estado do Rio de Janeiro, by radioimmuno assay (IRMA Active
IGFBP-3 DSL-6600 and IRMA Active IGF-1 DSL-5600). The
IGF-I extraction was done with an HCl ethanol solution. An anti-
IGF-I antibody marked with I-125 was used for IGF-I measure-
ments. The coefficients of variation were 3.0 for intra-assay
(means52.5 ng/mL; SDs16.4) and 1.5 for the inter-assay
(means53.8 ng/mL; SDs8.0) differences. An anti-IGFBP-3
polyclonal goat antibody marked with I-125 was used for
IGFBP-3 measurements. The coefficients of variation were 3.2
for the intra-assay (means27.23 ng/mL; SDs1.4) and 1.5 for
the inter-assay (means21.9 ng/mL; SDs0.1) differences.
Differences in proportions were evaluated using the x2-test
with Yates correction. A non-parametric test (Wilcoxon test) was
used for comparisons of the levels of IGF-I and IGFBP-3
between the groups, and a Spearman correlation was used to
analyze the relationship between these factors and birth weight,
head circumference, length at birth and ponderal index. All
analyses used the SAS (Statistic Analysis System, version 9.01)
software. The study was approved by the Ethics Committee
of the Institution, and one of the parents signed a written
informed consent.
Results
The mothers of 57 children were invited to participate,
and 54 (94.7%) agreed. Due to paired inclusion, 28 were
SGA (17 preterm) and 26 were AGA (15 preterm). The
demographic characteristics of the population are shown
in Table 1. There were no significant differences between
the two groups at birth, except for birth weight, birth
length, head circumference and weight for age Z-score
(P-0.0001).
On the first day of life, mean serum levels of IGFBP-3
but not of IGF-I were significantly lower in SGA babies
(Table 2). There were borderline correlations between
IGF-I and birth weight (0.28, Ps0.048) and IGF-I and the
ponderal index (0.27, Ps0.06). However, there were no
correlations between IGF-I and length at birth, head cir-
cumference at birth or gestational age (P-values of 0.12,
0.41 and 0.22, respectively). IGFBP-3 had a strong, posi-
tive correlation with birth weight (0.67, P-0.0001), birth
length (0.64, P-0.0001), head circumference (0.60,
P-0.0001), ponderal index (0.69, P-0.0001) and ges-
tational age (0.44, Ps0.001).
Discussion
In this study, no significant difference was found in the
IGF-I levels between SGA and AGA newborn infants on
the first day of life, although IGFBP-3 levels were lower
in SGA infants. This lack of difference between SGA and
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Table 2 Means, SD and 95% CI of IGF-I and IGFBP-3 serum levels for SGA and AGA newborn infants in the first day of life.
Variable SGA (26) AGA (25) P-value
Mean (SD) 95% CI Mean (SD) 95% CI
IGF-I (ng/dL) 2.78 (2.37) 1.82–3.74 3.99 (3.04) 2.73–5.24 0.17
IGFBP-3 (ng/dL) 541.9 (295.9) 455.4–628.5 682.4 (287.1) 597.2–767.6 0.007
Wilcoxon test.
SDsstandard deviation, CIsconfidence interval, SGAssmall for gestational age, AGAsappropriate for gestational age.
matched controls indicates the important role of gesta-
tional age in IGF-I changes. This observation is in agree-
ment with a previous study performed with fetal blood
samples that showed a progressive increase in IGF-
I levels with gestational age; by comparing the IGF-I lev-
els of small (below the mean weight for gestational age)
and large (above the mean weight for gestational age)
fetuses, the authors found lower levels in the small fetus,
although the difference between the groups was not sig-
nificant up to 33 weeks of gestation w18x. The infants
included in the present study are a heterogeneous popu-
lation in relation to gestational age, as they were selected
as SGA independent of gestational age, as were their
counterparts: about 60% in each group were preterm,
and 25.9% of the entire population had a gestational age
of -33 weeks.
Levels of IGF-1 for gestational age reported in fetal
samples throughout gestation have shown an increase
toward the end of gestation w9, 17, 18x. There are also
reports of IGF-I levels in cord blood w2, 22, 25, 30, 32x
and a decrease in IGF-I levels from cord blood to the first
and fourth days of life has been observed w10, 23, 29x.
However, Giudice et al. (1995) obtained different results,
showing that IGF-I levels were unchanged in preterm
newborn infants, whereas in term neonates IGF-I levels
decreased on day one, remained low during the first
three days of life, and then increased to birth levels by
the end of the first week w10x. In our study, blood was
collected on the first day of life from babies of different
gestational ages due to the matching by gestational age
and sex. Consequently, our IGF-I and IGFBP-3 values are
not comparable to those reported in the literature
because they represent mean values from preterm and
full-term neonates.
On the other hand, the lack of difference in IGF-I levels
between SGA and AGA infants on the first day of life
could be the effect of attenuation since approximately
one fourth of the babies had a gestational age of -33
weeks, where a difference in IGF-I levels between SGA
and AGA infants would not be expected. IGFBP-3 levels
have no correlation with gestational age w18x and, there-
fore, were not influenced by the prevalence of preterm
babies in this sample born at -33 weeks. Only two
previous reports of higher IGF-I levels in SGA newborn
infants w29, 32x and one report of a lack of difference in
IGF-I levels between AGA and SGA newborn infants w25x
were found.
In a study considering constitutional growth potential
based on maternal characteristics, Mamelle et al. (2006)
demonstrated that the group of infants classically clas-
sified as SGA was heterogeneous in respect to having
suffered in utero growth restriction: some were SGA by
weight and/or length but were in fact not growth restrict-
ed w24x. Additionally, some infants, classified as AGA by
weight and/or length, had suffered growth restriction
w24x. This could also happen in our population,
confounding the results of IGF-I on the first day of life.
Verkauskiene et al. (2007) showed that cord IGF-I and
IGFBP-3 concentrations were significantly decreased in
growth-restricted infants, defined by serial ultrasound
measurements during gestation, in both AGA and SGA
babies w31x. Their study used two classifications to define
growth restriction: 1) a reduction of )20% of the esti-
mated fetal weight from the 22nd gestational week until
birth, based on serial ultrasound scans, and 2) a classi-
fication at birth as AGA or SGA using the 10th percentile
of a customized growth chart as a cut-off. Similar to
Mamelle et al. (2006) w24x, Verkauskiene et al. (2007)
found AGA babies who were growth restricted and SGA
babies who were not growth restricted. In our study, we
tried to minimize this difficulty by using a more restricted
cut-off to define SGA: birth weight equal to or -2 SD
below the mean. In conclusion, the correct classification
of growth restriction in utero is extremely important for
understanding its effect on the hormonal status of the
newborn infant.
Although this study did not reveal differences in the
levels of IGF-I between the two groups of infants in the
first day of life, IGFBP-3 levels were lower in SGA babies
and strongly correlated with weight, length, head circum-
ference and ponderal index, demonstrating its role in fetal
growth here and in other studies w7, 13x. The apparent
disassociation between IGF-I and IGFBP-3 levels in this
particular situation may be explained by the actions of
IGFBP-3 w3, 4x. IGFBP-3 is the most abundant IGFBP
circulating in human serum, has both inhibitory and stim-
ulatory effects in cell systems, and modulates growth.
IGFBP-3 can prevent IGF-I from binding to its receptors
since IGF-I has a higher affinity to IGFBP-3 than to the
IGF-I receptor, thus having an inhibitory action on
growth. IGFBP-3 also functions as a reservoir of IGF-I,
carrying it to target cells w4x. In addition, IGFBP-3 not
only carries IGF-I to the target organs, but also activates
IGF-I receptors on target cells. However, IGFBP-3 alone
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has no direct stimulatory effect; it acts through activation
of IGF-I receptors. It has been demonstrated that IGFBP-
3 increases the bioeffectiveness of IGF-I by 2- to 4-fold
w5x. Therefore, the equal levels of IGF-I in both AGA and
SGA babies and lower levels of IGFBP-3 in SGA babies
may indicate that action of IGF-I is diminished by IGFBP-
3 reduction, resulting in the growth restriction of children.
In conclusion, this study demonstrates that IGFBP-3
plays an important role in promoting fetal growth and is
a good marker for evaluating in utero growth. However,
the classification of in utero growth restriction is funda-
mental to documenting this evidence. It is important to
identify these children at birth because they could be at
risk for metabolic diseases later in life.
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